Premium
O3‐01‐04: Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials
Author(s) -
Fleisher Adam S.,
Joshi Abhinay D.,
Sundell Karen,
Chen Yun-Fei,
Devous Michael D.,
Seibyl John,
Marek Kenneth,
Siemers Eric R.,
Mintun Mark A.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.239
Subject(s) - placebo , normalization (sociology) , white matter , nuclear medicine , medicine , psychology , magnetic resonance imaging , pathology , radiology , alternative medicine , sociology , anthropology
n1⁄459; p1⁄40.01), compared to placebo (n1⁄436). Increases in ventricular volume over 18 months of treatment were greater in the CEE group if initiation of hormone therapy occurred later in menopause, after adjusting for age (r1⁄40.40; p1⁄40.03). Rates of WMH increase were higher in the pooled treatment groups compared to placebo (p1⁄40.03). Rates of ventricular expansion correlated with rates of decrease in brain volume (r1⁄4-0.58; p1⁄4<0.001) and increase in WMH (r1⁄40.27; p1⁄40.01) after adjusting for age. Change in global cognitive function was not different across groups. Conclusions:Ventricular and WMH volumes increased to a greater extent in recently menopausal women given hormone therapy compared to placebo. However, these changes did not affect cognitive performance. Persistence of these imaging changes and their long term effects on cognition remain to be determined.